MannKind Corporation News Releases http://investors.mannkindcorp.com/ MannKind Corporation News Releases en MannKind to Present at the JMP Securities Life Sciences Conference http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-present-jmp-securities-life-sciences-conference WESTLAKE VILLAGE, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will Wed, 12 Jun 2019 09:00:00 -0400 MannKind Corporation News Releases 16446 MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-afrezzar-clinical-data-three-studies WESTLAKE VILLAGE, Calif. , June 09, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, Sun, 09 Jun 2019 14:00:00 -0400 MannKind Corporation News Releases 16441 Afrezza® (insulin human) Inhalation Powder Approved in Brazil http://investors.mannkindcorp.com/news-releases/news-release-details/afrezzar-insulin-human-inhalation-powder-approved-brazil Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. The innovative delivery system reduces injections while improving glycemic control in adult patients with diabetes WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil , June 03, 2019 (GLOBE Mon, 03 Jun 2019 08:00:00 -0400 MannKind Corporation News Releases 16436 MannKind Announces Afrezza® Distribution Agreement in Australia http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-afrezzar-distribution-agreement-australia WESTLAKE VILLAGE, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. Thu, 16 May 2019 16:01:00 -0400 MannKind Corporation News Releases 16341 MannKind Corporation Reports 2019 First Quarter Financial Results http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-first-quarter-financial Conference Call to Begin Today at 9:00 AM ET 1Q 2019 Total Revenues of $17.4 million 1Q 2019 Afrezza Net Revenue was $5.1 million ; +49% vs. 1Q 2018 1Q 2019 Collaborations and Services Revenue was $12.4 million 1Q 2019 net loss per share $(0.08) vs. $(0.25) in 1Q 2018; +68% improvement Received Tue, 07 May 2019 08:00:00 -0400 MannKind Corporation News Releases 16306 MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019 http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2019-first-quarter-financial-results WESTLAKE VILLAGE, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management will host a conference call to discuss the financial results and other Company developments at 9:00 AM Tue, 30 Apr 2019 09:00:00 -0400 MannKind Corporation News Releases 16301 MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019) http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-scientific-data-28th-annual-scientific-and WESTLAKE VILLAGE, Calif. , April 25, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be presented in an e-poster presentation on Thursday, April 25, 2019 at the 28 th Annual Scientific and Clinical Thu, 25 Apr 2019 09:45:00 -0400 MannKind Corporation News Releases 16286 MannKind to Present at the H.C. Wainwright Global Life Sciences Conference http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-present-hc-wainwright-global-life-sciences-conference WESTLAKE VILLAGE, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will Tue, 02 Apr 2019 06:00:00 -0400 MannKind Corporation News Releases 16266 MannKind Receives $12.5 Million Milestone Payment from United Therapeutics http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-125-million-milestone-payment-united WESTLAKE VILLAGE, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization Mon, 01 Apr 2019 06:00:00 -0400 MannKind Corporation News Releases 16261 MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-sponsor-andretti-autosport-type-1-diabetes-driver-conor IndyCar Driver Living with Diabetes Helps Raise Awareness for Diabetes Treatment Options WESTLAKE VILLAGE, Calif. , March 14, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Thu, 14 Mar 2019 09:00:00 -0400 MannKind Corporation News Releases 16241